Healthcare Policy Lobbyist (Biotech)
About The Initiative
The Clinical Trial Abundance Initiative exists to reform federal policy and law governing clinical trials, making them faster, cheaper, and simpler to conduct. Founded by a coalition of leading science philanthropies, the initiative aims to leverage the 2027 reauthorization of the Prescription Drug User Fee Act (PDUFA) to enact real reform and sustain momentum beyond it.
What This Role Is — And Isn't
This is a policy and law reform role, not an operations or access role. The work focuses on changing the rules governing clinical trials to enable more trials to be launched, run, and approved faster and at lower cost. The role does not involve operating or running trials, nor does it focus on trial access, diversity, inclusion, or equity. Instead, it aims to make trials themselves faster, cheaper, and more abundant by reforming the system that governs them.
Who You Are
- Deep credibility in biotech, life sciences, or FDA / clinical-trial policy
- A track record of being taken seriously by senior, varied stakeholders: Hill offices, agencies, industry executives, investors, and researchers
- Evidence of building something durable, not just winning a near-term legislative fight
- Fluent in the case for reform that expands what's possible — cutting the friction, cost, and time between good science and the patients who need it
Requirements
- Direct experience with PDUFA, user-fee reauthorizations, or FDA review-pathway reform
- Familiarity with international regulatory models (Australia, UK, EU)
- An existing network spanning biotech, investors, research, and DC policy
Nice to Have
- Direct experience with PDUFA, user-fee reauthorizations, or FDA review-pathway reform
- Familiarity with international regulatory models (Australia, UK, EU)
- An existing network spanning biotech, investors, research, and DC policy
Benefits
- Competitive salary of $200,000 - $250,000 USD/year
- Private Health Insurance
- Paid Time Off
- Work From Home
- Training & Development